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ABSTRACT
The efficiency of hematopoietic stem cell (HSC) engraft-
ment after bone marrow (BM) transplantation depends
largely on the capacity of the marrow microenvironment
to accept the transplanted cells. While radioablation of
BM damages osteoblastic stem cell niches, little is known
about their restoration and mechanisms governing their
receptivity to engraft transplanted HSCs. We previously
reported rapid restoration and profound expansion of the
marrow endosteal microenvironment in response to mar-
row radioablation. Here, we show that this reorganization
represents proliferation of mature endosteal osteoblasts
which seem to arise from a small subset of high-
proliferative, relatively radio-resistant endosteal cells.
Multiple layers of osteoblasts form along the endosteal
surface within 48 hours after total body irradiation, con-
comitant with a peak in marrow cytokine expression. This
niche reorganization fosters homing of the transplanted
hematopoietic cells to the host marrow space and engraft-
ment of long-term-HSC. Inhibition of insulin-like growth
factor (IGF)-1-receptor tyrosine kinase signaling abrogates
endosteal osteoblast proliferation and donor HSC engraft-
ment, suggesting that the cytokine IGF-1 is a crucial medi-
ator of endosteal niche reorganization and consequently
donor HSC engraftment. Further understanding of this
novel mechanism of IGF-1-dependent osteoblastic niche
expansion and HSC engraftment may yield clinical appli-
cations for improving engraftment efficiency after clinical
HSC transplantation. STEM CELLS 2013;31:2193–2204
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Adequate donor stem cell engraftment is essential to
achieve successful bone marrow transplantation (BMT). The
capacity for donor hematopoietic stem cells (HSCs) to
engraft within host bone marrow (BM) depends on their
interactions with specific microenvironments designated as
HSC niches [1–3]. Under homeostatic conditions, BM
niches nurture HSCs, maintaining the critical balance of
quiescence, self-renewal, and differentiation [4,5]. After
BMT, donor HSC must home to and engraft within these
niches and then markedly expand to repopulate the pool of
primitive hematopoietic cells within host marrow, ultimately
restoring the homeostatic milieu [6]. Thus, the relationship
of HSC’s with these niches is an intricate and dynamic
interaction [7].
Many recent studies have attempted to identify the cel-
lular components and complex regulatory networks govern-
ing HSC niche function [6,8,9]. Osteoblasts have been
described as a pivotal cellular component of the endosteal,
or osteoblastic niche [4,5,10]. Osteoblasts are known to sup-
port hematopoiesis in vitro [11,12]. Moreover, in situ deple-
tion of osteoblasts severely diminishes BM hematopoiesis
[13]. At homeostasis, many HSCs reside along the single
layer of osteoblasts that comprises the endosteal surface,
and following BMT, HSCs have been reported to localize to
this endosteal region [14,15]. Although other cellular
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elements such as endothelial cells also play key roles in
HSC niche function [9], these data suggest a critical role
for osteoblasts in supporting HSCs both during homeostasis
and after BMT.
We recently described a remarkable cellular remodeling
of the marrow architecture after hematopoietic cell ablation
with total body irradiation (TBI) in mice [16]. Marrow radioa-
blation initiates a program of striking endosteal osteoblast
expansion, accompanied by relocalization of surviving mar-
row elements, particularly megakaryocytes, to the expanded
endosteal surface. Endosteal expansion is accompanied by
significantly increased levels of stromal cell-derived factor
(SDF)-1, a critical regulator of HSC interactions with the
osteoblastic niche [17]. However, our prior study did not
investigate the functional significance of this cellular remodel-
ing in facilitating the complex process of HSC homing and
engraftment. Additionally, the specific cellular and molecular
pathways required for the remodeling response were not
defined.
Here, we present data suggesting that post-TBI endosteal
cell expansion fosters donor hematopoietic cell homing to the
marrow space as well as short- and long-term (LT) hemato-
poietic reconstitution. Moreover, insulin-like growth factor 1
(IGF-1), a known natural agonist of osteoblast growth and
proliferation [18], appears to be a critical regulator of marrow
remodeling and donor HSC engraftment. Collectively, our
data provide mechanistic evidence that the dynamic structural
reorganization of the osteoblastic niche following marrow
radioablation is vital for HSC engraftment and durable hema-
topoietic recovery post-transplantation.
MATERIALS AND METHODS
Animal Use and Care
All procedures were performed in accordance with protocols
approved by The Children’s Hospital of Philadelphia Institutional
Animal Care and Use Committee. Six- to twelve-week-old
C57BL/6 wild-type (WT) mice were purchased from Jackson
Laboratories (Bar Harbor, ME, http://www.jax.org). Transgenic
C57BL/6 mice expressing green fluorescent protein (GFP) under
control of the H2K promoter (H2K-GFP) [19] were used as
GFP1 BM donors in transplantation experiments. pOBCol2.3GF-
Pemd (COL2.3GFP) mice [20,21] were generously provided by
Dr. David Rowe (University of Connecticut; Farmington, CT).
Animals were housed under specific pathogen-free conditions.
Osteoblast Niche Expansion Studies
For irradiation experiments, animals received myeloablative TBI
(1,125 cGy) via an x-ray source (X-RAD 320: Precision X-Ray
Inc.; North Branford, CT, http://www.pxinc.com). To assess
osteoblastic niche changes post-TBI, WT or Col2.3GFP mice
were irradiated and then euthanized at specified time points after
TBI (30 minutes; 3, 6, 12, 18, 24, 48, 72, 96 hours; n 5 10 per
group). Mice not receiving TBI were used as comparison groups.
In a subset of experiments, irradiated mice received intraperito-
neal (i.p.) 50 mg/kg injections of BrdU (BD Biosciences; San
Diego, CA, http://www.bdbiosciences.com) 1 hour prior to eutha-
nasia except for time point analyses >24 hours post-TBI, when
BrdU was given 24 hours prior to euthanasia.
For histology and immunohistochemistry studies, femurs and
tibias were fixed in 10% formalin, decalcified for 3–5 days (Reg-
ular Cal•Immuno; BBC Biochemical; Stanwood, WA, http://
www.bbcus.com) and paraffin-embedded or decalcified for 3
weeks in 15% EDTA before preparing frozen sections using
O.C.T. compound (Sakura; Torrence, CA, http://www.sakura-
americas.com). For assessment of osteoblast proliferation and
individual osteoblast thickness, sections were stained with hema-
toxylin and eosin (H1E) (Sigma-Aldrich; St. Louis, MO, http://
www.sigmaaldrich.com), and semiquantitatively assessed in
blinded fashion to determine the osteoblast score index, repre-
senting the average number of endosteal lining cell layers per
section. At least five sections/mouse were scored and averaged to
provide an individual mouse score. Osteoblast thickness was
assessed by microscopic measurement (three sections/mouse)
using the AxioVision 4.5 SP1 software (Carl Zeiss, Thornwood,
NY, http://corporate.zeiss.com).
Immunostaining for BrdU, Ki-67, GFP, and IGF-1 was per-
formed using rat anti-BrdU antibody (1:50) (Roche; Mannheim,
Germany, https://www.roche-applied-science.com), rabbit anti-
Ki67 antibody (Abcam; Cambridge, MA, http://www.abcam.-
com), rabbit anti-GFP antibody (Invitrogen; Carlsbad, CA, http://
www.invitrogen.com), and rabbit anti-IGF1 antibody (Abbiotec;
San Diego, CA, http://www.abbiotec.com) along with goat anti-
rat/rabbit biotinylated secondary antibody (1:180), avidin/biotin
complexes, and NovaRED peroxidase development (Vector Labo-
ratories; Burlingame, CA, http://www.vectorlabs.com). Target-
specific staining was verified by performing negative control
staining with rabbit and rat isotype control primary antibodies
(Vector, BD Biosciences). Slides were examined using a Zeiss
Axiovert 200M (Carl Zeiss) with either a 103/0.25NA or a 403/
0.6NA dry objective. All photomicrographs were acquired with
the attached AxioCam HR color camera and analyzed using Axi-
oVision 4.5 SP1 software (Carl Zeiss).
To assess ex vivo primary osteoblast growth and colony for-
mation from pre- and post-TBI mice, BM was flushed from
femurs, and the endosteal bone surface was denuded by vigorous
scraping using a 26 g needle. Denudation of the endosteal lining
cells was confirmed by histologic analysis (Supporting Informa-
tion Fig. S1). The resulting cell suspension was plated in osteo-
blast growth media (50/50 Dulbecco’s modified Eagle’s medium/
F-12 with 10% fetal bovine serum, glutamate, pen/strep, and 25
lg/ml ascorbic acid) for 7 days. Plates were then washed with
plain phosphate buffered saline, and adherent cells were fixed to
the plate in 4% paraformaldehyde, permeabilized with 0.1% Tri-
ton X-100, and immunostained for osteocalcin expression using a
rabbit-anti-mouse osteocalcin polyclonal antibody (Takara Bio
Inc.; Otsu, Japan, http://www.clontech.com/takara), a biotinylated
secondary anti-rabbit antibody, avidin-biotin complexes, and 3,30-
Diaminobenzidine substrate (Vector). Numbers and size (diame-
ter) of osteocalcin positive colonies were counted using the Zeiss
Axiovert (Carl Zeiss).
Growth Factor Expression Analyses
To assess BM growth factor expression, femurs from euthanized
pre- and post-TBI mice were collected, and marrow was flushed
with phosphate buffered saline using a 26 g needle. For protein
analysis, BM was flushed with 1 ml of phosphate buffered saline
containing protease inhibitor (Roche), followed by addition of
Nonidet P-40 (United States Biological; Swampscott, MA, http://
www.usbio.net) (1%, vol/vol). Cells were lysed by freeze/thaw
three times, and cell debris removed by centrifugation at 14,000g
for 5 minutes. Platelet-derived growth factor-BB (PDGF-BB),
transforming growth factor beta (TGFb), basic fibroblast growth
factor (bFGF), SDF-1, and IGF-1 protein concentrations were
measured by ELISA (R&D Systems; Minneapolis, MN, http://
www.rndsystems.com) according to manufacturer’s instructions.
For quantitative PCR (qPCR) analysis, total RNA was iso-
lated from flushed BM cells using TRIzol Reagent (Invitrogen).
First-strand cDNA was synthesized using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems; Foster
City, CA, http://www.appliedbiosystems.com), per manufacturer’s
protocol. qPCR (7500 Fast Real-Time PCR System, Applied Bio-
systems) was performed using target-specific primers (Supporting
Information Table S1) and SYBR Green PCR Master Mix system
(Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogen-
ase expression was used to normalize for RNA input. Reaction
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conditions for amplification were: 95C for 10 minutes, then 50
cycles of: 95C for 15 seconds and 55C–60C for 60 seconds.
All samples were measured in duplicate.
Homing and Transplantation Studies
For BMT studies, whole BM from transgenic mice with pan-
cellular expression of GFP under the control of the H2K pro-
moter (H2K-GFP) [19] or Sca-1-depleted BM from syngeneic
WT mice was injected into the lateral tail vein at a dose of 3 3
106 cells per recipient. Sca-1 depletion was performed by sorting
the 7-amino-actinomycin D2 Sca-12 fraction from whole BM
(Supporting Information Fig. S2), using a FACSAria III cell
sorter (BD Biosciences).
BM was infused either immediately (0-hour), 24 hours, or 48
hours after recipient irradiation (1,125 cGy). In initial homing
studies, BM was collected 6 or 24 hours after transplant, red
blood cells (RBCs) were lysed, and BM was stained with propi-
dium iodide and assessed by flow cytometry for the percentage
of live BM cells expressing GFP. All flow cytometry experi-
ments were performed on a FACSCalibur with Cellquest soft-
ware or FACSAria cell sorter with FACSDiva software (BD
Biosciences).
Competitive repopulation secondary transplantation assays
were performed as follows. Three cohorts (six mice/cohort) of
WT mice received 3 3 106 GFP BM cells 30 minutes, 24 hours,
or 48 hours post-TBI. Twenty-four hours after primary BMT, pri-
mary recipients were euthanized, and all BM from bilateral
femurs and tibias were collected and pooled within each cohort.
Using a previously defined dosing scheme in which all bilateral
femur and tibia BM represents a 25% BM equivalent (BME)
dose [22], a 12.5% BME dose derived from each of the primary
recipient groups was injected into three separate groups of WT
secondary recipient mice (n 5 10/group) irradiated 24 hours prior
to secondary BMT. Each secondary recipient also received 2 3
105 whole BM cells from an unirradiated WT mouse, serving as
a competitor HSC population. Three to eighteen weeks after sec-
ondary transplantation, secondary recipients were analyzed by
flow cytometry for GFP1 cell reconstitution in peripheral blood
lineages, including RBCs and platelets determined by forward
and side scatter, along with myeloid cell, T-cell, and B-cell popu-
lations defined by staining with anti-mouse Gr1 (clone RB6-
8C5), CD3e (clone 1452c11), and B220 (clone RA36B2) antibod-
ies (BD Biosciences).
IGF-1 Signaling Blockade
To assess the contribution of IGF-1 to niche proliferation and
function following irradiation, we treated irradiated WT C57BL/6
mice with i.p. injection of either the IGF-1 receptor tyrosine
kinase inhibitor picropodophylin (PPP, 20 mg/kg per dose, Cal-
biochem: EMD Biosciences Inc.; San Diego, CA, http://
www.emdmillipore.com) or vehicle alone (dimethyl sulfoxide/oil,
9:1) at the time of and 12 hours after TBI. At 48 hours post-TBI,
mice were euthanized and assessed for osteoblast proliferation as
above. A second cohort of irradiated mice (n 5 6/group) that
were untreated, PPP-treated, or sham-treated received 3 3 106
GFP1 BM cells 48 hours post-TBI and were then assessed as dis-
tinct primary recipient cohorts for relative HSC engraftment effi-
ciency by competitive secondary transplant assay, as detailed
above.
Statistical Methods
Data are presented as mean 6 SD. Data were analyzed by two-
tailed Student’s t test for mean comparisons, by Fisher’s Exact
test for percent positive comparisons or by one-way analysis of
variance (ANOVA) for multiple comparisons. Statistical analyses
were performed by Microsoft Excel 2010 (Microsoft; Redmond,
WA, http://www.microsoft.com) or Prism, Version 4 (GraphPad
Inc.; San Diego, CA, http://www.graphpad.com). Statistical sig-
nificance was defined as p < .05.
RESULTS
Complete Osteoblast Niche Expansion After Marrow
Radioablation Requires 48 Hours
We previously demonstrated that marrow radioablation indu-
ces an increase in the number of layers of marrow endosteal
cells 48 hours post-irradiation [16]. These cell layers con-
sisted of large cells with eccentric nuclei and abundant cyto-
plasm representing N-cadherin1 osteoblasts and smaller cells
with a central nucleus and spindle-shaped body consistent
with stromal fibroblasts or other mesenchymal elements. We
began this study by defining the time course of osteoblast
niche expansion post-irradiation, the cellular composition of
this expanded population, and the nature of this proliferation.
We first examined murine BM prior to and at multiple
time points after lethal irradiation (1,125 cGy), to determine
the time course of endosteal cell proliferation. We used both
qualitative examination of sections (Fig. 1A) along with
blinded quantitative histologic scoring in which the osteoblast
proliferation index equated to the predominant number of
endosteal cell layers present (Fig. 1B). Confirming our previ-
ous findings, prior to irradiation a single layer of endosteal
cells lines the surface of metaphyseal trabecular bone (Fig.
1A, upper left). Endosteal cells formed a single continuous
layer of bone-lining cells by 3 hours post-TBI, which
remained the predominant endosteal cell configuration
through 18 hours (Fig. 1B). As hematopoietic marrow cells
began to dissipate, significant expansion of endosteal cells
was visualized at 24 hours, corresponding to approximately
half-maximal cell expansion (Fig. 1A, upper right and 1B).
By 48 hours (Fig. 1A, bottom left and 1B), the endosteal cell
expansion reached near-maximal levels, with three to four
cell layers lining the endosteal surface (p < .01 by one-way
ANOVA). No further expansion occurred by either 72 or 96
hours post-TBI, although the endosteal surface remained
expanded to three to four layers during this period (Fig. 1A,
bottom right and 1B; p < .01 by one-way ANOVA). In addi-
tion to the increase in cell layers at 48 hours post-TBI, indi-
vidual cells along the bone surface demonstrated significantly
increased cell thickness (2.5-fold; p 5 .0001 by t test) com-
pared to endosteal cells prior to irradiation (Fig. 1C). Interest-
ingly, this finding parallels what has been described for the
endosteal compartment stimulated after G-CSF mobilization
of HSCs [23], suggesting osteoblast activation following TBI
exposure that may alter osteoblast adhesive properties for
primitive hematopoietic cells [24].
Expanded Osteoblast Niche Consists
of Mature Osteoblasts
The endosteal niche consists of many cell types, including
osteoblasts, monocytes, fibroblasts, mesenchymal stromal
cells, and other stromal elements [12]. Given the diverse mor-
phology of the expanded population of endosteal cells, we
sought to determine which endosteal cells underwent prolifer-
ation after marrow radioablation. We examined postradiation
endosteal changes in transgenic mice in which GFP was
expressed under the control of the Col1a1 (collagen) 2.3 kb
promoter, as GFP expression in this strain is limited to mature
osteoblasts and is not present in fibroblasts, other stromal ele-
ments, or hematopoietic cells [20,21]. Using immunofluores-
cence to directly assess GFP expression (Fig. 1D) or through
performing immunohistochemistry with an anti-GFP antibody
(Fig. 1E), we unequivocally found that the vast majority of
endosteal cell expansion 48 hours post-TBI was due to
increased numbers of GFP1 mature osteoblasts.
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Clustered Proliferative Endosteal Cells Drive
Niche Expansion
To further define mechanisms driving osteoblast expansion
after radioablation, we focused on the endosteal region of tra-
becular bone, staining sections for Ki-67 expression, a recog-
nized cell proliferation marker [25]. Ki-67 expression in
endosteal cells of trabecular bone was minimal up to 3 hours
after TBI (data not shown). However, by 6 hours post-TBI,
isolated cells and small clusters along the metaphyseal bone
surface began to express Ki-67 (Fig. 2A, upper left panel)
and, from 24 to 48 hours post-TBI, Ki-67 expression by
osteoblasts was widespread and prominent (Fig. 2A, upper
middle and right panels). To further confirm active prolifera-
tion of endosteal osteoblasts after irradiation, mice were also
injected once with BrdU (bromodeoxyuridine) following irra-
diation. BrdU uptake was seen in discrete, isolated small
groups of endosteal lining cells beginning 6 hours post-TBI
and BrdU1 cells significantly increased in clusters by 24
hours post-TBI (Fig. 2A, bottom left and middle panels). At
48 hours after irradiation, as expected, the number of BrdU-
labeled cells declined (Fig. 2A, bottom right panels) suggest-
ing that the cells that originally incorporated BrdU, at 24
hours post-TBI, continued to proliferate.
Together, these data suggested that post-TBI osteoblast
expansion may have arisen from a small subset of osteo-
blasts with high proliferative potential, analogous to colony-
forming units (CFUs) characteristic of primitive hematopoi-
etic progenitors and mesenchymal cells. To test this
Figure 1. Time course of endosteal osteoblast expansion following TBI. (A): Representative H1E stained sections of BO and BM and (B)
quantitative analysis (mean 6 SEM, 8–10 mice each time point) showing the time course of endosteal osteoblast expansion following radioabla-
tion (1,125 cGy). *, p < .01 versus baseline. (C): Representative H1E stained sections and quantitative assessment (mean 6 SEM, three sec-
tions/mouse, three mice/group) of individual osteoblast thickness at baseline and 48 hours after TBI. *, p 5 .0001 versus baseline. (D):
Immunofluorescent staining (GFP, green; DAPI, blue) and (E) immunohistochemistry staining (GFP stained brown, black arrowheads) of BO/BM
sections before and 48 hours after TBI, taken from COL2.3GFP mice, showing the marked increase in GFP1 mature osteoblasts at the endosteal
surface 48 hours after TBI. Abbreviations: BM, bone marrow; BO, bone; GFP, green fluorescent protein; TBI, total body irradiation.
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hypothesis, we harvested BM and endosteal lining cells from
mouse femurs either before TBI or from 6 to 96 hours post-
TBI, cultured those cells for 7 days, and analyzed the num-
ber and size of osteocalcin1 osteoblast colonies within those
cultures (Fig. 2B, 2C). No significant osteoblast colonies
formed in the hematopoietic/endosteal cell cultures taken
from unirradiated mice, which was consistent with hemato-
poietic cell-induced suppression of osteoblast growth. How-
ever, cells harvested between 6 and 18 hours post-TBI
formed 30–40 colonies per well with an average colony
diameter of 3 mm, indicating a remarkable in vitro prolifera-
tion of the CFU-initiating cells. From 6 to 96 hours post-
TBI, the colony-forming potential of these cells progres-
sively and significantly declined, with a 90% reduction in
colony formation at 24, 48, 72, and 96 hours compared to
that seen 6 hours post-TBI (p < .01 by one-way ANOVA).
In addition, the size of colonies significantly decreased after
TBI (p < .01 by one-way ANOVA), becoming 65% smaller
than the average colony size seen at 6 hours post-TBI.
These in vitro data strongly support the hypothesis that this
in vivo increase of endosteal cells following TBI occurs
through a proliferation program mediated initially by a select
subset of proliferative osteoblasts.
Growth Factor Expression and Hematopoietic Cell
Regulation of Osteoblastic Niche Expansion
Many growth factors, including PDGF-BB, TGFb, bFGF, and
IGF-1 are critical regulators of osteoblast growth and differ-
entiation during normal development [26–28]. In turn, osteo-
blasts secrete the chemokine SDF-1 that serves as a potent
chemoattractant, activating signal, and antiapoptotic factor for
a variety of hematopoietic cells including HSC [29]. We ana-
lyzed the expression of these growth factors before TBI and
during the osteoblast expansion response post-TBI (Fig. 3A).
The time course analyses of protein (Fig. 3A) and mRNA
(Fig. 3B) expression revealed a progressive and significant
increase of SDF-1, PDGF-BB, bFGF, TGFb, and IGF-1 (p <
.05 for protein expression and p  .01 for mRNA expression
by one-way ANOVA) of up to threefold by 48 hours post-
TBI, compared to unirradiated BM levels. Interestingly, the
increased expression of each of these growth factors corre-
lated temporally with the expansion of the osteoblastic niche,
shown earlier (Fig. 1B).
We then specifically focused on IGF-1 as a potential criti-
cal mediator involved in TBI-induced osteoblast expansion, as
IGF-1 is a potent mediator of osteoblast proliferation [18] and
may have a general role in niche regulation [30].
Figure 2. TBI-induced endosteal niche expansion arises from an osteoblast subset with high proliferative potential. (A): Immunostaining dem-
onstrating expression of Ki-67 (brown-stained cells [arrowheads], upper panels) and BrdU incorporation (brown-stained cells [arrowheads], lower
panels) in metaphyseal endosteal osteoblasts at 6, 24, and 48 hours after TBI. (B): Representative adherent cell culture colony growth, stained at
7 days for osteocalcin1 osteoblasts, from BM and endosteal surface cells harvested from mice before and 6, 24, 48, and 96 hours post-TBI. (C):
Quantitative analysis (mean 6 SEM) of colony number (left) and average colony size (right) in the adherent cell cultures at baseline and 6–96
hours post-TBI (n  5 per group). *, p < .01 versus 6 hours post-TBI. Abbreviations: BM, bone marrow; BO, bone; TBI, total body irradiation.
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Immunohistochemical staining for BM IGF-1 expression per-
formed at 48 hours post-TBI revealed increased expression
compared to that seen in unirradiated controls (Fig. 3C), with
the highest level of expression localized to endosteal osteo-
blasts, suggesting that a substantial fraction of the increased
marrow IGF-1 (Fig. 3A, 3B) may arise from osteoblast
secretion.
We next postulated that the endosteal osteoblast prolifera-
tion and increased expression of growth factors might be due
to the absence of tonic inhibitory signals provided by hemato-
poietic cells, and specifically by primitive marrow cells
demarcated by Sca-11 expression. To test this hypothesis, we
compared osteoblast niche expansion at 48 hours post-TBI in
mice receiving whole BMT immediately after TBI versus irra-
diated but not transplanted mice. In contrast to mice receiving
TBI only (Fig. 4A, left), mice receiving whole BMT immedi-
ately after TBI (Fig. 4A, middle) did not exhibit significant
osteoblastic niche expansion by 48 hours post-TBI, showing
Figure 3. Osteoblast growth factor expression following TBI. (A): Protein expression (normalized per BM cell, mean 6 SEM) of SDF-1,
PDGF-BB, bFGF, TGFb, and IGF-1 in BM isolated from either unirradiated (NI) or 3–96 hours post-TBI WT mice (n 5 3–5 mice/time point).
*, p  .01 versus expression in NI group. (B): qPCR analysis of SDF-1, PDGF-BB, bFGF, TGFb, and IGF-1 relative mRNA (normalized to
GAPDH) expression in BM cells isolated from unirradiated or 3–72 hours post-TBI WT mice (mean 6 SD, n 5 3 per time point, except IGF-1
data expressed as mean 6 SEM, n 5 2–6 per time point). *, p  .01 versus expression in NI group. (C): Representative immunostained BO and
BM sections demonstrating increased expression of IGF-1 (brown-red-stained cells, arrowheads) at the metaphyseal endosteum at 48 hours post-
TBI (bottom) versus baseline (top). Abbreviations: bFGF, basic fibroblast growth factor; BM, bone marrow; BO, bone; IGF-1, insulin-like growth
factor 1; PDGF, platelet-derived growth factor; TBI, total body irradiation; TGFb, transforming growth factor beta.
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only a single layer of endosteal cells, as in the controls prior to
irradiation (Fig. 4B, significantly decreased vs. no BMT group,
p < .05 by one-way ANOVA). However, irradiated mice who
received Sca-11 cell-depleted BM immediately after TBI
(Fig. 4A, right) still developed osteoblastic niche expansion
similar to that seen after 48 hours post-TBI in nontransplanted
mice (significantly increased vs. pre-TBI and whole BM BMT
groups, p < .05 by one-way ANOVA), suggesting that the
Sca-11 fraction of transplanted marrow cells, which contains
HSCs and progenitors, prevents or rapidly reverses endosteal
osteoblast expansion. Furthermore, in contrast to the marked
increased expression of SDF-1, PDGF-BB, TGFb, bFGF, and
IGF-1 by BM cells at 48 hours post-TBI (Figs. 3A, 4C) rela-
tive to baseline pre-TBI levels, BM expression of these cyto-
kines at 48 hours post-TBI in mice receiving BMT
immediately after TBI (Fig. 4C) was less than or equal to base-
line pre-TBI expression levels (significantly decreased from
TBI only groups, p < .001 by one-way ANOVA). Collectively,
these data suggest that Sca-11 cells negatively regulate the
reversible BM niche reorganization after TBI and BMT.
Hematopoietic Cell Homing and HSC
Engraftment Following BMT Are Enhanced by
Radioablation-Induced Osteoblast Proliferation
Based on the observation that BM Sca-11 hematopoietic cells
appear to play a regulatory role in osteoblastic niche expan-
sion/reversion after BMT, we next sought to determine
whether the expansion itself could represent a compensatory
mechanism designed to improve homing and engraftment of
HSCs in response to a sensed loss of BM. We performed ini-
tial BM homing assays using a GFP1 transgenic mouse as a
BM donor and WT mice as BMT recipients. BMT performed
48 hours post-TBI, the time of maximal osteoblast niche
expansion resulted in a trend toward greater initial GFP1
donor cell homing to BM within the first 6 hours post-BMT
than homing seen when BMT was performed either immedi-
ately (0 hour) or 24 hours after TBI (Fig. 5A), although this
trend did not reach statistical significance (p 5 .20). Strik-
ingly, BM engraftment of GFP1 donor cells, measured 24
hours after BMT (Fig. 5B), significantly increased in mice
Figure 4. Early BMT following TBI prevents osteoblast niche expansion. (A): H1E stained BO and BM sections and (B) quantitative scoring
analysis (right) comparing endosteal osteoblast expansion at baseline (Pre-TBI) and 48 hours post-TBI (left) in mice receiving (immediately after
irradiation) either BMT with whole BM (3 3 106 cells), BMT with Sca-11 cell-depleted BM (3 3 106 cells), or no BMT. *, p < .05 versus pre-
TBI and whole BM BMT groups. (C): SDF-1, PDGF-BB, bFGF, TGFb, and IGF-1 protein expression in isolated BM cells harvested from unirra-
diated mice (pre-TBI), mice 48 hours post-TBI with no other treatment (TBI only), and mice 48 hours post-TBI who received 3 3 106 whole
BM cells immediately after TBI (TBI 1 BMT) (n 5 3–5 per group). *, p < .001 versus pre-TBI or TBI 1 BMT groups. Abbreviations: BM,
bone marrow; BMT, bone marrow transplantation; BO, bone; IGF-1, insulin-like growth factor 1; TBI, total body irradiation; TGFb, transforming
growth factor beta.
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transplanted 48 hours after TBI versus mice transplanted
either immediately or 24 hours after TBI by 20- and 14-fold,
respectively (p  .05 by one-way ANOVA).
To assess whether osteoblast niche expansion specifically
enhances HSC engraftment, we performed a competitive repo-
pulation secondary transplantation assay, in which GFP1 BM
was transplanted into WT primary (1) recipient mice at vari-
able times post-TBI, selected on the basis of the expansion
time course data presented in Figure 1B. We performed 1
BMT either immediately (0 hour) after TBI when no osteo-
blastic niche expansion had occurred, at 24 hours post-TBI
when niche expansion was beginning, or 48 hours post-TBI
when expansion reached near maximal levels. In this assay,
24 hours after 1 BMT, BM was harvested from 1 recipients
Figure 5. Maximal osteoblastic niche expansion increases initial donor cell homing to bone marrow (BM) and durable long-term hematopoietic
stem cell/progenitor engraftment. (A): Donor GFP1 cell homing to BM, expressed as the percentage of live GFP1 BM cells (mean 6 SEM,
n 5 4 mice per group), at 6 and (B) 24 hours post-BMT in WT mice receiving 3 3 106 GFP1 whole BM cells either 0, 24, or 48 hours after
TBI, with representative histograms shown for each group. *, p < .05 versus immediately (0 hours) or 24 hours post-TBI. (C, D): Competitive
repopulation secondary transplantation assay in which primary (1) recipient WT mice were transplanted with 3 3 106 GFP1 whole BM at 0, 24,
or 48 hours post-TBI. 1 recipient BM was then harvested at 24 hours post-1 BMT and transplanted into WT secondary (2) recipient mice with
2 3 105 unirradiated WT whole BM competitor cells. Data are expressed as the percentage of GFP1 cells in each peripheral blood lineage
(GR11 myeloid cells, B2201 B cells, CD31 T cells, RBC, or platelets) in 2 recipient mice at 3 weeks (C) and 18 weeks (D) post-2 BMT. Sig-
nificantly increased GFP1 2 recipients (>2% GFP1 cells, dashed line) in indicated blood cell lineage versus 0 hour (*, p < .05) or 24 hour
(1, p < .05) groups. Abbreviations: BMT, bone marrow transplantation; GFP, green fluorescent protein; TBI, total body irradiation.
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and transplanted with competitor BM cells into irradiated sec-
ondary (2) recipient mice. Thus, the percentage of 2 recipi-
ents with GFP1 hematopoiesis, defined as >2% GFP1 cells
within peripheral blood RBC, platelet, myeloid cell, and
lymphocyte lineages, directly reflects HSC engraftment effi-
ciency in 1 recipients transplanted either immediately (0
hour), 24 hours, or 48 hours post-TBI.
At 3 weeks post-2 recipient BMT (Fig. 5C), when most
hematopoiesis was derived from short-term (ST)-HSC or pro-
genitor cells, GFP1 hematopoietic reconstitution within each
lineage increased more than fivefold in 2 recipients of BM
from 1 recipients transplanted 48 hours post-TBI versus
immediately after TBI (p < .05 by Fisher’s Exact test), dem-
onstrating significantly increased ST-HSC and progenitor
engraftment efficiency when BMT was performed at the time
of maximal osteoblast niche expansion.
At 18 weeks post-2 BMT (Fig. 5D), when hematopoiesis
is solely dependent upon LT-HSC engraftment, 2 recipients
of BM from 1 recipients that received BMT immediately
after TBI had no significant GFP1 cell engraftment, whereas
the majority of 2 recipients whose BM came from 1 recipi-
ents transplanted 48 hours post-TBI retained significant GFP1
reconstitution of RBC, platelet, myeloid, and lymphocyte line-
ages (p < .05 vs. 0 and 24 hour groups by Fisher’s Exact
test). These data demonstrate that LT-HSC engraftment sig-
nificantly increased when BMT was performed at the time of
maximal niche expansion.
IGF-1 Signaling Blockade Disrupts Both
Radioablation-Induced Osteoblastic Niche Expansion
and Efficient HSC Engraftment Following BMT
IGF-1 is crucial for skeletal bone development [18] and, indi-
rectly, for the developmental formation of the endosteal niche
[31]. Moreover, IGF-1 plays a role in the regulatory niche of
pluripotent stem cells [30]. Thus, having identified a striking
increase in marrow IGF-1 after radioablation concomitant
with endosteal niche expansion and HSC engraftment (Figs.
3A, 3B, 4C), we hypothesized that this cytokine may be a
key regulator of the HSC endosteal niche. To test this idea,
we treated mice with picropodophyllin (PPP), a potent and
selective IGF-1 receptor tyrosine kinase inhibitor [32] with a
short half-life (t1/2  3 hours). PPP was administered
just before TBI and again 12 hours after TBI. At 48 hours
post-TBI, we observed a nearly complete abrogation of
TBI-induced osteoblast expansion (Fig. 6A).
We then performed an additional competitive repopulation
2 transplantation assay similar to that described above, test-
ing irradiated 1 recipients that received either no other treat-
ment, IGF-1 signaling inhibition using PPP, or sham vehicle
(dimethyl sulfoxide) treatment at the time of TBI. Once again,
using GFP1 reconstitution of 2 recipients at 3 weeks and 18
weeks as a measure of 1 recipient ST-HSC/progenitor and
LT-HSC engraftment efficiency, respectively, we found that
both ST-HSC (Fig. 6B; *, p < .05 by Fisher’s Exact test) and
LT-HSC (Fig. 6C; *, p < .05 by Fisher’s Exact test) engraft-
ment were severely diminished when osteoblast niche expan-
sion was blocked by PPP-mediated IGF-1 signaling inhibition.
Intravenous infusion of IGF-1 at the time of TBI, however,
did not enhance osteoblast expansion or stem cell engraftment
(Supporting Information Fig. S3), most likely because either
the concentration of the systemically infused IGF-1 in the
marrow microenvironment was insufficient or physiologic
osteoblast niche expansion is maximal. Nonetheless, these
findings further confirm the critical importance of osteoblast
niche expansion following TBI in the facilitation of stem cell
engraftment, and they identify IGF-1-driven signaling as a
critical direct mediator of TBI-induced niche expansion and
an indirect mediator of HSC engraftment.
DISCUSSION
Our data demonstrate that the remarkable reorganization of
the endosteal niche following radioablation that we described
previously [16] consists of expansion of proliferating endosteal
osteoblasts and serves critical functions for donor hematopoi-
etic cell homing and both short-term and LT-HSC engraftment
in the recipient BM space following BMT. Moreover, we have
begun to elucidate cellular and molecular pathways inherent in
this niche response, demonstrating that signaling through the
IGF-1 receptor drives proliferation of mature osteoblasts from
a small subset of primitive mesenchymal progenitors with
high proliferative potential. The ability to block hematopoietic
cell engraftment by inhibition of IGF-1-mediated niche expan-
sion provides compelling evidence for the key role of endo-
steal niche expansion in facilitating efficient HSC engraftment.
Moreover, complete elucidation of the molecular and
cellular pathways of the niche reorganization may provide
novel targets to enhance HSC engraftment in clinical trans-
plantation. Exploiting such strategies would be invaluable in
the setting of limited stem cell doses, such as increasingly
used cord blood transplantation methods as well as in HSC
transplantation for diseases that are biologically resistant to
engraftment.
The specific signal that triggers the initiation of post-TBI
osteoblastic niche expansion remains unknown. One possibil-
ity is that direct radiation toxicity to the mesenchymal niche
elements, including osteoblasts, could initiate this reorganiza-
tion as a damage-repair mechanism. However, the expanded
niche post-TBI vastly exceeds the number of niche elements
present at baseline, and it is rare for this type of over-
correction to occur in physiologic repair mechanisms. Our
data showing that early transplantation following TBI with
whole BM, but not Sca-11 cell-depleted BM, can rapidly
reverse or possibly block niche expansion and the associated
increased expression of mesenchymal growth factors suggest
that disruption of crosstalk between Sca-11 hematopoietic
cells and the endosteal niche cells initiates the observed
osteoblast expansion program. Hematopoietic cells within the
Sca-11 fraction may actively suppress osteoblast proliferation,
or conceivably, HSC occupancy of the endosteal niche after
BMT may regulate osteoblast proliferation through adhesion
molecules or signaling. Interruption of these interactions by
marrow ablation may release the restraint that leads to osteo-
blast proliferation. From a teleological perspective, such a
mechanism may have evolved as a survival mechanism to
maintain and recruit HSCs within the niche following infec-
tious or environmental exposures that cause HSC toxicity.
Thus, the cellular reorganization may be viewed as an activa-
tion of the endosteal niche to bind circulating HSCs and rees-
tablish hematopoiesis after environmental injury.
Based on our Ki-67 and BrdU immunostaining assays,
post-TBI niche expansion originates in a few relatively radio-
resistant high proliferative potential cells. Our in vitro colony
assays demonstrated that these progenitors undergo colony-
type proliferation beginning soon after TBI, giving rise pri-
marily to maturing osteoblasts, as demonstrated in our in vivo
Col2.3GFP mouse model, in which only mature osteoblasts
express GFP [20,21]. Although the majority of the increased
population of endosteal cells post-TBI in this model are
GFP1 osteoblasts, a small percentage are GFP2, suggesting
that other mesenchymal cell types also known to play critical
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roles in homeostatic niche function [33] must also be present
in the expanded endosteal microenvironment post-TBI. Thus,
although mature osteoblasts are the predominant population
within the niche post-TBI, the relative contributions of bone-
generating osteoblasts versus other minority niche elements
post-TBI in providing specific HSC binding sites and/or func-
tionally enabling engraftment require further study.
The kinetics of niche expansion following TBI appears to
be strain-dependent, as osteoblast expansion in the C57BL/6
mice used in this study occurred faster than we previously
observed in FVB/N mice [16]. Such murine strain variation in
niche expansion may be related to strain-dependent mesen-
chymal proliferation capacity, which we previously reported
[34]. The kinetics of our C57BL/6 model have the advantage
of allowing us to comparatively investigate HSC homing and
engraftment at times of no expansion (immediately after
TBI), 50% expansion (24 hours post-TBI), and >95% (maxi-
mal) expansion (48 hours post-TBI). This comparison demon-
strates clear superiority of HSC engraftment efficiency when
BMT is performed at 48 hours post-TBI, the time of maximal
osteoblast expansion. Whether an osteoblastic niche expansion
response exists in human subjects undergoing BMT after
radioablation and whether it follows similar kinetics remains
unknown. Thus, optimization of clinical BMT timing in
Figure 6. Blockade of insulin-like growth factor 1 (IGF-1) signaling disrupts both TBI-induced osteoblast proliferation and hematopoietic stem
cell engraftment following bone marrow (BM). (A): H1E stained BM sections demonstrating marked reduction in 48 hour post-TBI osteoblast
niche expansion (arrowheads) in WT mice receiving TBI and the IGF-1-receptor tyrosine kinase inhibitor PPP (20 mg/kg) (right) versus mice
receiving TBI only (left). (B, C): Competitive secondary (2) transplantation assay in which untreated, vehicle-treated (DMSO), or PPP-treated
primary (1) recipient mice received BMT (3 3 106 GFP1 whole BM cells) at 48 hours post-TBI, and competitive 2 BMT was performed 24
hours after 1 BMT with 1 recipient BM and 2 3 105 unirradiated WT BM cells. Data reflect the percentage of GFP1 cells in specified periph-
eral blood lineages at 3 weeks (B) and 18 weeks (C) post-2 BMT in 2 recipients of untreated, vehicle-treated, or PPP-treated primary recipient
BM. Significantly decreased GFP1 2 recipients (>2% GFP1 cells, dashed line) in indicated blood cell lineage versus untreated (*, p < .02) or
vehicle-treated (1, p < .05) groups. Abbreviations: BMT, bone marrow transplantation; GFP, green fluorescent protein; PPP, picropodophylin;
TBI, total body irradiation.
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relation to radioablation and its initiation of niche prolifera-
tion would require large-animal studies or human-subject
translational research.
Our novel finding that IGF-1 signaling is required for
TBI-induced niche osteoblast proliferation and subsequent
measurable HSC engraftment in our model is consistent with
the well-described essential role that IGF-1 plays in modulat-
ing osteoblast growth during development and under homeo-
static conditions [35]. IGF-1 signaling inhibition with PPP, a
specific small-molecule inhibitor with a short half-life (t1/2 
3 hours) [32], could not have directly affected the trans-
planted donor hematopoietic cells, given that the final dose
was administered 36 hours before transplantation. Thus, our
model allows us to test the effects of inhibiting IGF-1 in the
BM microenvironment, or elsewhere within the host, without
affecting IGF-1-dependent pathways in donor HSC. Osteo-
blasts produce IGF-1, which influences growth through both
paracrine and autocrine pathways [28]. IGF-1 is also an
essential downstream mediator of parathyroid hormone effects
on osteoblast growth [36]. Thus, the previously reported
increase in baseline HSC in mice with transgenic osteoblast-
specific parathyroid hormone receptor upregulation [4] may
also rely upon IGF-1 signaling. Additionally, IGF-1 is also
known to stimulate osteoblast secretion of vascular endothe-
lial growth factor (VEGF) [37], and thus may also play a role
in VEGF receptor-2 signaling previously shown to be required
for hematopoietic reconstitution following BMT [9].
CONCLUSION
In sum, we have shown that endosteal niche expansion fol-
lowing radioablation reflects proliferation of mature osteo-
blasts from relatively infrequent radio-resistant cells in a time
course that parallels the expression of osteoblast growth fac-
tors. HSC engraftment efficiency is superior when BMT is
performed during maximal osteoblast expansion. IGF-1 sig-
naling blockade completely abrogates both osteoblast niche
expansion as well as measureable HSC engraftment following
transplantation. Taken together, our data demonstrate the
critical importance of IGF-1-driven reorganization of the BM
microenvironment, and specifically the osteoblastic niche, in
enabling efficient HSC engraftment following transplantation.
Further understanding of these niche expansion pathways will
allow identification of therapeutic strategies to improve HSC
engraftment in the clinical BMT setting.
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